Table 1.
Comparison of clinicopathological profiles and prognosis among four subgroups based on glomerular PLA2R antigen staining and serum PLA2R ab test.
| All | SAb−/GAg− | SAb+/GAg− | SAb+/GAg+ | SAb−/GAg+ | p Value | |
|---|---|---|---|---|---|---|
| No (%) | 372 | 54 (14.52) | 7 (1.89) | 201 (54.03) | 110 (29.57) | - |
| PLA2R ab (RU/mL) | 28.22 (3.50, 96.38) | 1.41 (1.08, 2.24) | 240.10 (74.17, 369.18) | 78.59 (42.95, 158.81) | 4.57 (1.65, 9.47) | <0.01 |
| Female (%) | 135 (36.29) | 22 (40.74) | 4 (57.14) | 71 (35.32) | 38 (34.55) | 0.57 |
| Age (y) | 56.00 (43.75, 64.00] | 53.50 (38.75, 64.00) | 53.00 (44.00, 63.50) | 57.00 (46.00, 65.00) | 54.00 (41.50, 62.00) | 0.50 |
| Microscopic Hematuria (%) | 174 (46.77) | 22 (40.74) | 4 (57.14) | 96 (47.76) | 52 (47.27) | 0.76 |
| Urine protein (g/24 h) | 5.71 (4.11, 8.25) | 5.39 (3.97, 6.79) | 6.84 (4.45, 8.19) | 6.38 (4.33, 9.06) | 5.09 (3.64, 7.37) | 0.01 |
| Albumin (g/L) | 21 (17, 26) | 23.5 (17, 28) | 14 (13, 21) | 21 (16, 25) | 23.5 (18, 29) | <0.01 |
| eGFR-EPI (mL/min × 1.73 m2) | 99.13 (78.61, 113.92) | 101.88 (87.33, 113.94) | 99.71 (85.91, 119.00) | 96.07 (74.60, 113.58) | 99.62 (86.55, 112.13) | 0.48 |
| Uric acid (umol/L) | 350.5 (295.5, 401.3) | 352.0 (297.0, 391.0) | 319.0 (302.5, 363.5) | 350.0 (293.0, 403.0) | 352.0 (300.5, 401.5) | 0.87 |
| Hypertension (%) | 170 (45.70) | 12 (22.22) | 3 (42.86) | 101 (50.25) | 54 (49.09) | <0.01 |
| Diabetes Mellitus (%) | 52 (13.98) | 7 (12.96) | 1 (14.29) | 31 (15.42) | 13 (11.82) | 0.84 |
| Treatment (%) | 0.1 | |||||
| Pred + CTX | 123 (33.06) | 16 (29.63) | 3 (42.86) | 73 (36.32) | 31 (28.18) | |
| pred + CSA | 138 (37.10) | 19 (35.19) | 3 (42.86) | 80 (39.80) | 36 (32.73) | |
| ACEI/ARB | 95 (25.54) | 19 (35.19) | 1 (14.29) | 38 (18.91) | 37 (33.64) | |
| RTX | 16 (4.30) | 0 (0.00) | 0 (0.00) | 10 (4.98) | 6 (5.45) | |
| Secondary causes (%) | 43 (11.56) | 13 (24.07) | 1 (14.29) | 19 (9.45) | 10 (9.09) | 0.02 |
| Pathology stage (%) | <0.01 | |||||
| I | 77 (20.70) | 21 (38.89) | 0 (0.00) | 31 (15.42) | 25 (22.73) | |
| II | 246 (66.13) | 24 (44.44) | 6 (85.71) | 143 (71.14) | 73 (66.36) | |
| III + IV | 49 (13.17) | 9 (16.67) | 1 (14.29) | 27 (13.43) | 12 (10.91) | |
| Tubulo-interstitial lesions ≥ 25(%) | 8 (2.15) | 0 (0.00) | 0 (0.00) | 6 (2.99) | 2 (1.82) | 0.56 |
| Prognosis * (N) | 329 | 41 | 6 | 182 | 100 | |
| Follow-up time (m) | 79.20 (48.70, 97.40) | 84.00 (51.77, 98.43) | 85.23 (60, 97.40) | 74.55 (28.65, 80.13) | 84.22 (44.63, 106.75) | 0.22 |
| Death (%) | 13 (3.95) | 2 (4.88) | 1 (16.67) | 8 (4.40) | 2 (2.00) | 0.29 |
| ESRD (%) | 38 (11.55) | 3 (7.32) | 2 (33.33) | 27 (14.84) | 6 (6.00) | 0.04 |
| Tumor (%) | 12 (3.65) | 0 (0.00) | 0 (0.00) | 6 (3.30) | 6 (6.00) | 0.33 |
| Thrombosis (%) | 25 (7.60) | 3 (7.32) | 1 (16.67) | 14 (7.69) | 7 (7.00) | 0.86 |
| Decrease in eGFR ≥ 30% (%) | 73 (22.19) | 4 (9.76) | 4 (66.67) | 47 (25.82) | 18 (18.00) | <0.01 |
| 6m remission (%) | 183 (55.62) | 30 (73.17) | 1 (16.67) | 87 (47.80) | 65 (65.00) | <0.01 |
| 24m remission (%) | 281 (85.41) | 39 (95.12) | 5 (83.33) | 145 (79.67) | 92 (92.00) | 0.01 |
Continuous variables presented as mean± SD or median (IQR); Abbreviations: pred + CTX: prednisone combined with cyclophosphamide; pred + CSA: prednisone combined with cyclosporine. ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Aldosterone Receptor Blockers; RTX: Rituximab. * Prognosis: patients with secondary causes were removed to reduce confounders in prognosis analysis.